WilmerHale represented the underwriters in connection with the $90 million initial public offering of Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic diseases of the retina and optic nerve. Graybug Vision’s shares began trading on the Nasdaq Global Market on September 25, 2020.

The WilmerHale team included partners Lisa Firenze and Chris Barnstable-Brown, counsel Craig Hilts, senior associate Hilary-Baker Jennings and associate Lugar Choi on corporate and capital markets matters, with support from Bruce Manheim, Colleen Superko and Heidi Treiber.